Elanco Animal Health Inc (NYSE:ELAN) shares traded -2.19% lower at $10.27 on Wall Street last session.
ELAN stock price is now -12.86% away from the 50-day moving average and -6.24% away from the 200-day moving average. The market capitalization of the company currently stands at $5.06B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $14, Barclays recently Upgraded its rating from Equal Weight to Overweight for Elanco Animal Health Inc (NYSE: ELAN).
In other news, HOOVER R DAVID, Director bought 5,000 shares of the company’s stock on Mar 14. The stock was bought for $47,750 at an average price of $9.55. Upon completion of the transaction, the Director now directly owns 165,000 shares in the company, valued at $1.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13, Director HOOVER R DAVID bought 5,000 shares of the business’s stock. A total of $47,288 was incurred on buying the stock at an average price of $9.46. This leaves the insider owning 160,000 shares of the company worth $1.64 million. Insiders disposed of 402,517 shares of company stock worth roughly $4.13 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ELAN stock. A new stake in Elanco Animal Health Inc shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $51,042,000. H PARTNERS MANAGEMENT, LLC invested $35,175,000 in shares of ELAN during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Elanco Animal Health Inc valued at approximately $32,371,000. PRIVATE MANAGEMENT GROUP INC acquired a new stake in ELAN for approximately $9,865,000. WOODLINE PARTNERS LP purchased a new stake in ELAN valued at around $7,290,000 in the second quarter. In total, there are 583 active investors with 98.19% ownership of the company’s stock.
Elanco Animal Health Inc (NYSE: ELAN) opened at $10.55 on Wednesday. During the past 12 months, Elanco Animal Health Inc has had a low of $7.88 and a high of $14.69. As of last week, the company has a debt-to-equity ratio of 0.82, a current ratio of 2.84, and a quick ratio of 1.53. The fifty day moving average price for ELAN is $11.76 and a two-hundred day moving average price translates $10.94 for the stock.
The latest earnings results from Elanco Animal Health Inc (NYSE: ELAN) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.18, beating analysts’ expectations of $0.05 by 0.13. This compares to -$0.02 EPS in the same period last year. The net profit margin was -2.24% and return on equity was -1.33% for ELAN. The company reported revenue of $1.06 billion for the quarter, compared to $1.18 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.04 percent. For the current quarter, analysts expect ELAN to generate $1.04B in revenue.
